An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg

Completed

Conditions studied: Breast Cancer

In brief

To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to letrozole

Key facts

Study ID

NCT00291109

Run by

University of Kansas

People needed

40

Starts

2003-01-01

Expected to finish

2005-07-01

Last updated by the study team

2008-09-16

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast
• on hormone replacement therapy
• postmenopausal
• increased risk of developing breast cancer based on personal or family history
• never have taken aromatase inhibitors or selective estrogen receptor modulators in last six months
• women who have a high risk of breast cancer
• older than 18 years

You may not qualify if…

• no anticoagulants
• no marked breast tenderness
• not pregnant or within twelve months of breast feeding/childbirth

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.